First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-559, an Oral Inhibitor of the Helicase DHX9, in Patients With Locally Advanced or Metastatic Solid Tumors and Molecularly Defined Cancers
Sponsor: Accent Therapeutics
Terminated
The study was terminated by sponsor based on the adverse event profile.
This PHASE1 trial investigates Advanced Solid Tumors and Breast Cancer Recurrent and is currently terminated or withdrawn. Accent Therapeutics leads this study, which shows 10 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1
-
Sep 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Feb 2025 [monthly]
Recruiting PHASE1
First recorded
Oct 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Accent Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .